Skip to content

FDA OKs Blueprint’s pralsetinib for certain type of lung cancer

September 8, 2020

Under accelerated review status, the FDA approves Blueprint Medicine’s (NASDAQ:BPMC) Gavreto (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC).

The company will co-commercialize the once-daily RET inhibitor in the U.S. with Roche’s Genentech. Market launch will commence within one week.

Roche will commercialize ex-U.S. excluding Greater China.

Management will host a webcast this morning at 8:00 am ET to discuss the nod.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: